siRNA mediated knockdown of EphA2 or treatment with ephrinA1-Fc revert the erlotinib and gefitinib (reversible tyrosine kinase inhibitors) resistance in NSCLC [14]. This evidence concerns the gene EPHA2 and non-small cell lung carcinoma.